| Literature DB >> 34956057 |
Kajol Marathe1, Ali Alim-Marvasti1,2,3, Karan Dahele1, Fenglai Xiao1, Sarah Buck1, Aidan G O'Keeffe4, John S Duncan1,2, Vejay N Vakharia1,2.
Abstract
Objectives: One-third of individuals with focal epilepsy do not achieve seizure freedom despite best medical therapy. Mesial temporal lobe epilepsy (MTLE) is the most common form of drug resistant focal epilepsy. Surgery may lead to long-term seizure remission if the epileptogenic zone can be defined and safely removed or disconnected. We compare published outcomes following open surgical techniques, radiosurgery (SRS), laser interstitial thermal therapy (LITT) and radiofrequency ablation (RF-TC).Entities:
Keywords: LITT = laser interstitial thermal therapy; MTLE = mesial temporal lobe epilepsy; epilepsy; radiofrequency ablation (RFA); radiosurgery; surgery
Year: 2021 PMID: 34956057 PMCID: PMC8695716 DOI: 10.3389/fneur.2021.777845
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Figure 1PRISMA flowchart.
Open surgery patient characteristics.
|
|
|
|
|
|---|---|---|---|
| ATLR | 206 R | 33 (from nine studies) | 25.5 (from 10 studies) |
| SAH (transcortical) | 170 R | 35.1 (from 9 studies) | 24.6 (from nine studies) |
| SAH (transsylvian) | 39 R (from two studies) | 34.1 (from three studies) | 25.4 |
[only stated in Wendling et al. (.
Open surgery.
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|
| Bate et al. | 2007 | Retrospective | ATLR | Transcortical SAH | ATLR: 82 | 12 months | ATLR: 62% (51/82) | 16/24 |
| SAH: 32 | SAH: 34% (11/32) | |||||||
| Bujarski et al. | 2013 | Retrospective | ATLR | Transcortical SAH | ATLR: 30 | 60 months | ATLR: 77% (23/30) | 15/24 |
| SAH: 39 | SAH: 69% (27/39) | |||||||
| Mansouri et al. | 2014 | Retrospective | ATLR | Transcortical SAH | ATLR: 75 | 24 months | ATLR: 51% (38/75) | 15/24 |
| SAH: 21 | SAH: 43% (9/21) | |||||||
| Nascimento et al. | 2016 | Retrospective | ATLR | Transcortical SAH | ATLR: 22 | 60 months | ATLR: 63.6% (14/22) | 18/24 |
| SAH: 23 | SAH: 73.9% (17/23) | |||||||
| Paglioli et al. | 2006 | Prospective | ATLR | Transcortical SAH | ATLR: 80 | ATLR: 80.4 months | ATLR: 91.3% (73/80) | 14/24 |
| SAH: 81 | SAH: 54 months | SAH: 86.4% (70/81) | ||||||
| Sagher et al. | 2012 | Retrospective | ATLR | Transcortical SAH | ATLR: 51 | ATLR: 43.2 months | ATLR: 92.2% (47/51) | 15/24 |
| SAH: 45 | SAH: 44.7 months | SAH: 95.6% (43/45) | ||||||
| Tanriverdi et al. | 2008 | Retrospective | ATLR | Transcortical SAH | ATLR: 50 | 60 months | ATLR: 64% (32/50) | 17/24 |
| SAH: 50 | SAH: 64% (32/50) | |||||||
| Tanriverdi et al. | 2010 | Retrospective | ATLR | Transcortical SAH | ATLR: 123 | 12 months | ATLR: 65.9% (81/123) | 16/24 |
| SAH: 133 | SAH: 58.6% (78/133) | |||||||
| Elliott et al. | 2018 | Retrospective | ATLR | Transcortical SAH | ATLR: 61 | 63.6 months | ATLR: 77% (47/61) | 17/24 |
| SAH: 18 | SAH: 44% (8/18) | |||||||
| Mohan et al. | 2018 | Retrospective | ATLR | Transcortical SAH | ATLR: 178 | 60 months | ATLR: 49% (87/178) | 16/24 |
| SAH: 37 | SAH: 31% (11/37) | |||||||
| Foged et al. | 2018 | Prospective | ATLR | Transcortical SAH | ATLR: 34 | 12 months | ATLR: 73.5% (25/34) | 18/24 |
| SAH: 22 | SAH: 72.7% (16/22) | |||||||
| Arturo Alonso-Vanegas et al. | 2018 | Prospective | ATLR | Transcortical SAH | ATLR: 14 | 60 months | ATLR: 64.3% (9/14) | 3/5 |
| SAH: 15 | SAH: 66.7% (10/15) | |||||||
| Clusmann et al. | 2002 | Retrospective | ATLR | Transsylvian SAH | ATLR: 98 | 38 months | ATLR: 69% (68/98) | 16/24 |
| SAH: 138 | SAH: 70% (96/138) | |||||||
| Lee et al. | 1997 | Retrospective | ATLR | Transsylvian SAH | ATLR: 25 | 12 months | ATLR: 60% (15/25) | 17/24 |
| SAH: 13 | SAH: 38.5% (5/13) | |||||||
| Morino et al. | 2006 | Retrospective | ATLR | Transsylvian SAH | ATLR: 17 | 12 months | ATLR: 71% (12/17) | 16/24 |
| SAH: 32 | SAH: 78% (25/32) | |||||||
| Schramm et al. | 2011 | Prospective | ATLR | Transsylvian SAH | ATLR: 74 | 12 months | ATLR: 83.8% (62/74) | 5/5 |
| SAH: 125 | SAH: 67.2% (84/125) | |||||||
| Wendling et al. | 2013 | Retrospective | ATLR | Transsylvian SAH | ATLR: 49 | 84 months | ATLR: 85.7% (42/49) | 18/24 |
| SAH: 46 | SAH: 78.3% (36/46) | |||||||
| Arruda et al. | 1996 | Retrospective | ATLR | Unspecified SAH | ATLR: 37 | 12 months | ATLR: 68% (25/37) | 17/24 |
| SAH: 37 | SAH: 76% (28/37) | |||||||
| Mackenzie et al. | 1997 | Retrospective | ATLR | Unspecified SAH | ATLR: 72 | 12 months | ATLR: 60% (43/72) | 15/24 |
| SAH: 28 | SAH: 21% (6/28) |
Figure 2Forest plots of effect sizes and 95% confidence intervals. (A) ATLR. (B) SAH trans-cortical. (C) SAH trans-sylvian. (D) Radiofrequency thermocoagulation. (E) Stereotactic radiosurgery. (F) LITT. (G) Comparison of treatment effect estimates.
Radiofrequency.
|
|
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|---|---|
| Parrent et al. | 1999 | Unclear | Radiofrequency | N/A | 19 | 25.8 months | 22% (4/19) | 9/16 |
| Vojtech et al. | 2014 | Retrospective | Radiofrequency | N/A | 61 | 63.6 months | 70.5% (43/61) | 10/16 |
| Fan et al. | 2019 | Prospective | Radiofrequency | N/A | 21 | 12 months | 76.2% (16/21) | 11/16 |
| Moles et al. | 2018 | Retrospective | Radiofrequency | ATLR | Radiofrequency: 21 | 12 months | Radiofrequency: 0% (0/21) | 16/24 |
| ATLR:49 | ATLR: 75.5% (37/49) |
Stereotactic radiosurgery.
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|
| Barbaro et al. | 2009 | Prospective RCT (low dose vs high dose) | Gamma Knife | Low dose vs high dose | 30 | 36 months | 67% (20/30) | 3/5 |
| Barbaro et al. | 2018 | Prospective RCT (ROSE trial) | Gamma Knife | ATLR | Gamma | 36 months | Gamma Knife: 52% (16/31) | 3/5 |
| ATLR: 27 | ATLR: 78% (21/27) | |||||||
| Bartolomei et al. | 2008 | Retrospective | Gamma Knife | N/A | 15 | 96 months | 60% (9/15) | 9/16 |
| Regis et al. | 2000 | Retrospective | Gamma Knife | N/A | 16 | 24 months | 81% (13/16) | 8/16 |
| Regis et al. | 2004 | Prospective | Gamma Knife | N/A | 20 | 24 months | 65% (13/20) | 11/16 |
| Rheims et al. | 2008 | Retrospective | Gamma Knife | N/A | 13 | 60 months | 38.5% (5/13) | 10/16 |
| Vojtech et al. | 2009 | Retrospective | Gamma Knife | N/A | 8 | 91.5 months | 12.5% (1/8) | 9/16 |
Laser interstitial thermal therapy.
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| Gross et al. | 2018 | Retrospective | LITT | 58 | 12 months | 53.4% (31/58) | 10/16 |
| Jermakowicz et al. | 2017 | Retrospective | LITT | 23 | 12 months | 65% (15/23) | 10/16 |
| Kang et al. | 2015 | Retrospective | LITT | 11 | 12 months | 36.4% (4/11) | 10/16 |
| Vakharia et al. | 2018 | Retrospective | LITT | 25 | 24.4 months | 44% (11/25) | 11/16 |
| Youngerman et al. | 2018 | Retrospective | LITT | 30 | 12 months | 57% (17/30) | 12/16 |
| Donos et al. | 2018 | Retrospective | LITT | 43 | 20.3 months | 67.4% (29/43) | 9/16 |
| Wu et al. | 2019 | Retrospective | LITT | 231 | 12 months | 58.0% (134/231) | 10/16 |
| Le et al. | 2018 | Prospective | LITT | 29 | 18 months | 62% (18/29) | 11/16 |
| Cajigas et al. | 2019 | Retrospective | LITT | 26 | 42.9 months | 61.5% (16/26) | 11/16 |
| Tao et al. | 2018 | Prospective | LITT | 21 | 24 months | 52% (11/21) | 13/16 |
| Grewal et al. | 2018 | Retrospective | LITT | 23 | 34 months | 65.2% (15/23) | 10/16 |